What is One Nucleus doing at BIO 2013?
Bio Executive Dinner, Sunday 21 April 2013, Hyatt Regency Chicago (Fully subscribed but read on)
We are holding a dinner in collaboration with Biocat, BIA and our two California MOU partners BayBio and BIOCOM. Hosted by AstraZeneca, there is nothing too formal as far as agenda goes, but a chance ahead of the main show to mingle with biotech execs from other geographical regions and learn peer-to-peer about what is going on elsewhere whilst extending your own network of contacts.
We are fortunate to have an array of sponsors in addition to the partners above in the shape of World Business Chicago, Prosonix, Niels Clauson-Kaas, Imanova and Scrip Intelligence who is our headline sponsor. On this note, Christopher Bowe of Scrip Intelligence will be speaking after dinner. If you would like to speak with Christopher during BIO and wish to make direct contact, he can be reached at Christopher.Bowe@informausa.com
Whilst the dinner is fully subscribed there IS the opportunity to join us to network. Whilst the dinner is due to run from 18.45 – 21.30hrs on Sunday, I have suggested to our guests that they may wish to network before and after the dinner in the DaddyO’s Irish Pub within the hotel venue where there is a cash bar and they do serve food. So even if you aren’t attending the dinner but at a loose end on Sunday evening, perhaps come along to join the networking opportunity. Looking forward to seeing you there.
Bio Executive Breakfast Debate, Monday 22 April 2013, Hyatt Regency Chicago (Fully subscribed)
This is the second annual debate One Nucleus has held in collaboration with Stockholm Uppsala Life Sciences (SULS), BIOCOM and BayBio at the BIO Convention. This year we will focus on ‘The role of Open Innovation in successful global partnerships’ where we hook up again with John Carroll of Fierce Biotech who will be chairing the event. The panel members consist of Erik Forsberg (Uppsala BIO), Joseph Panetta (BIOCOM), Gail Maderis (BayBio), Steven Powell (Virttu Biologics) and Steve Bates (BIA).
We are fortunate to have sponsors in the form of Uppsala BIO, Virttu Biologics and SULS.
I shall be attending events led by others including UK Trade & Investment, Technologiepark Heidelberg GmbH and Life Sciences Queensland and will be networking furiously.
Catch up with me at BIO: What are we talking about?
I imagine BIO2013 will be like previous BIO events in the sense that I will end up in some conversations on topics I could never have predicted! Nonetheless useful – all the time gaining knowledge and contacts that I can then factor in to later One Nucleus events, introductions and activities that benefit our One Nucleus members where possible. Focus is also key at BIO. I will spend much time at BIO reinforcing the key One Nucleus messages – that we aim to support our members in maximising their global competitiveness, that we are a great platform to bring the right people together across borders (as evidenced by the dinner and breakfasts at BIO as examples) and collaborating for member benefit where appropriate.
We have two major events in 2013
ON Helix (see http://www.onhelix.com/) taking place on 9 July 2013 in Cambridge
ON Helix is our brand new translational research conference for the life science industry and academia.
A one day event aimed at informing delegates of how to turn early stages inventions and ideas into innovative health treatments (new medicines, novel biomarkers, useful medical devices or improved medical practices).
It will present the UK landscape of the business environment, funding, scientific and clinical research excellence and will be a unique knowledge-sharing environment between academia and business.
Keynote Speakers already confirmed include: Sir William Castell, Sir Mike Rawlins, Andy McMenemy and other speakers of particular note include Prof. Mike Stratton and Prof Laurence Pearl.. Sponsors include MedImmune and UK Trade & Investment.
Genesis 2013 (http://www.genesisconference.com/) 11 – 12 December 2013, London
Now in its 13th year Genesis is the most established life science conference of its type now running in the UK. Attracting 650+ delegates each year into this unique thought leadership forum in one of the World’s most accessible, dynamic and influential cities Genesis continues to evolve. Key highlights for 2013 will include:
• Plenary Session with presentations from Dame Sally Davies, Sir Salvador Moncada, Roel Bulthuis and Mike Ward
• 4 x selected case study deal sessions led by Scrip Intelligence
• 2 x Bio-Pharma Partnering Showacse sessions
• 5 Therapeutic Area or Technology Focus thematic leadership sessions
• 1-2-1 Partnering
• The Scrip – One Nucleus Plenary Debate
• Pre-Conference Day hosted by the Canadian High Commission which will include the 2013 BioNewsRound Award and Welcome Reception
Who are we talking to?
I am a true believer in business being a people driven process and networks are key…. but then you may feel I am biased (ha ha).
I list below the companies and organisations that have registered one or more attendees to participate in our two BIO events detailed in this blog as a starting point, but I guess the wonder of BIO each year is that you will also meet many contacts known and unknown as part of the experience….
|Abel & Imray||Discuva||Public Health England|
|Archivelfarma||Governor’s Office of California||Roslin Foundation|
|BerGenBio AS||Hayhurst Associates||SGS North America|
|BIA||Imanova||South San Francisoco City|
|Biocat||Innova Biosciences||Stockholm Uppsala Life Sciences|
|BIOCOM||Kymab||Swiss Precision Diagnostics|
|Bionure||London & Partners (US)||Team Cailfornia|
|Biopharmacueticals Australia||Lykera Biomed||TechNation|
|BioWorld Today||Mass Life Sciences Center||The Institute of Cancer Research|
|British Consulate LA||MediWales||Tiberend Strategic Advisors, Inc|
|Caixa Capital Risc||Niels Clauson-Kaas A/S||UC San Diego|
|Canale Communications||Norgine||UKTI Boston|
|CantabIP||One Nucleus||University of West of England|
|Cleveland IP||Oryzon||Uppsala Bio|
|Cobra Biologics||Osborne Clarke||Vetter Pharma|
|College Hill||Pinsent Masons||Virdis Group|
|Communication Strategy Group||Plasmia Biotech||Virttu Biologics|
|Cushman & Wakefield of San Diego||Polytherics||W P Thompson|
|Datamonitor Healthcare Consulting||Prosonix||Withers & Rogers|
|World Business Chicago|
Written by Tony Jones, Director of Business Development, One Nucleus